+

SG11201900468YA - Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof - Google Patents

Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof

Info

Publication number
SG11201900468YA
SG11201900468YA SG11201900468YA SG11201900468YA SG11201900468YA SG 11201900468Y A SG11201900468Y A SG 11201900468YA SG 11201900468Y A SG11201900468Y A SG 11201900468YA SG 11201900468Y A SG11201900468Y A SG 11201900468YA SG 11201900468Y A SG11201900468Y A SG 11201900468YA
Authority
SG
Singapore
Prior art keywords
gprc5d
mckean
road
antibodies
pennsylvania
Prior art date
Application number
SG11201900468YA
Inventor
Ricardo Attar
Diana Chin
Suzanne Edavettal
Francois Gaudet
Yingzhe Li
Leopoldo Luistro
Nathan Majewski
Mark Mendonca
Kondandaram Pillarisetti
Alexey Teplyakov
Mark Tornetta
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SG11201900468YA publication Critical patent/SG11201900468YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/91—Cell lines ; Processes using cell lines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property - C.-- - .` Organization 1111111111101110101011111 01111101 0 11111010 110111111101 111111111111111 0111111 International Bureau (10) International Publication Number 03 (43) International Publication Date .../ WO 2018/017786 A3 25 January 2018 (25.01.2018) WI P0 I P C T (51) International Patent Classification: (72) Inventor; and C07K 16/28 (2006.01) A61P 35/02 (2006.01) (71) Applicant: ATTAR, Ricardo [US/US]; 1400 McKean A61K 39/395 (2006.01) Road, Spring House, Pennsylvania 19477 (US). (21) International Application Number: (72) Inventors: CHIN, Diana; 1400 McKean Road, Spring PCT/US2017/042982 House, Pennsylvania 19477 (US). EDAVETTAL, Suzanne; 1400 McKean Road, Spring House, Pennsylva- (22) International Filing Date: 20 July 2017 (20.07.2017) nia 19477 (US). GAUDET, Francois; 3210 Merryfield Row, La Jolla, 92121 (UA). LI, Yingzhe; 1400 McKean (25) Filing Language: English Road, Spring House, Pennsylvania 19477 (US). LUISTRO, Leopoldo; 1400 McKean Road, Spring House, Pennsyl- (26) Publication Language: English vania 19477 (US). MAJEWSKI, Nathan; 1400 McKean (30) Priority Data: Road, Spring House, Pennsylvania 19477 (US). MEN- 62/364,811 20 July 2016 (20.07.2016) US DONCA, Mark; 1400 McKean Road, Spring House, Penn- sylvania 19477 (US). PILLARISETTI, Kondandaram; (71) Applicant: JANSSEN PHARMACEUTICA NV 1400 McKean Road, Spring House, Pennsylvania 19477 [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE). (US). TEPLYAKOV, Alexey; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). TORNETTA, Mark; _ (54) Title: ANTI- GPRC5D ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND GPRC5D AND CD3, USES THEREOF AND = = Figure 1 = 35000 — 30000 Ei GP RC5D Cells lug/ml = • 293F lOugjmi e 4) 25000 • 293F tug/ml — O = — °.' d 20000 = = 2 is000 0 D ii _ C 10(100 = 2 — = 2 5000 II—IL e. .. l€11. = .4 I , 0 ,, .—, . vi vi •-.1 EN r.s EN = b 11 V_) :2 ) :3 2 i J .-1 ,,-„ 72. n A Ai 6 .T- . v 2. c N A o ,R, :' , „: L 'i ',' y j 0 t . 9 0 0 0 0 5 0 ,., T 'D ID 6 0 ID = = — = — _ = M Vr; (57) : Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable * t of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or anti- IN N gen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, meth- 1-1 ods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor --.., © GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; Ot or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a C 1-1 GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein. ei O [Continued on next page] WO 2018/017786 A3 MUNRO DOI 01011MERIONIMMEMEROMEfin 1400 McKean Road, Spring House, Pennsylvania 19477 (US). (74) Agent: SHIRTZ, Joseph F. et al.; JOHNSON & JOHNSON, One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(U)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a)) (88) Date of publication of the international search report: 01 March 2018 (01.03.2018)
SG11201900468YA 2016-07-20 2017-07-20 Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof SG11201900468YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662364811P 2016-07-20 2016-07-20
PCT/US2017/042982 WO2018017786A2 (en) 2016-07-20 2017-07-20 Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof

Publications (1)

Publication Number Publication Date
SG11201900468YA true SG11201900468YA (en) 2019-02-27

Family

ID=60992891

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900468YA SG11201900468YA (en) 2016-07-20 2017-07-20 Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof

Country Status (29)

Country Link
US (4) US10562968B2 (en)
EP (1) EP3487882B1 (en)
JP (3) JP7292200B2 (en)
KR (3) KR20250073578A (en)
CN (2) CN116333133A (en)
AR (2) AR109499A1 (en)
AU (2) AU2017299673B2 (en)
BR (1) BR112019001055A2 (en)
CA (1) CA3031472A1 (en)
CL (4) CL2019000146A1 (en)
CO (1) CO2019001114A2 (en)
CR (1) CR20190025A (en)
DK (1) DK3487882T3 (en)
EA (1) EA201990346A1 (en)
EC (1) ECSP19012075A (en)
FI (1) FI3487882T3 (en)
IL (2) IL298277A (en)
IN (1) IN201917002488A (en)
LT (1) LT3487882T (en)
MA (1) MA45712A (en)
MX (3) MX2019000825A (en)
NI (1) NI201900005A (en)
PE (2) PE20190392A1 (en)
PH (1) PH12019500152A1 (en)
SG (1) SG11201900468YA (en)
TW (1) TWI781108B (en)
UY (1) UY37340A (en)
WO (1) WO2018017786A2 (en)
ZA (1) ZA201901066B (en)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI744242B (en) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Antibody constructs for egfrviii and cd3
TWI796283B (en) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Antibody constructs for msln and cd3
TWI829617B (en) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Antibody constructs for flt3 and cd3
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide assembly and methods of making and using the same
DK3411404T3 (en) 2016-02-03 2023-01-30 Amgen Res Munich Gmbh PSMA-AND CD3-BISPECIFIC T CELL-ENGINEERING ANTIBODY CONSTRUCTS
EA039859B1 (en) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Bispecific antibody constructs binding egfrviii and cd3
TWI781108B (en) 2016-07-20 2022-10-21 比利時商健生藥品公司 Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof
WO2018035710A1 (en) * 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
WO2018147245A1 (en) * 2017-02-07 2018-08-16 第一三共株式会社 Anti-gprc5d antibody and molecule containing same
TW201932482A (en) 2017-11-01 2019-08-16 美商奇諾治療有限公司 Chimeric antigen receptor and polynucleotide encoding specific for B cell maturation antigen
TWI829667B (en) * 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 Antibodies binding to gprc5d
WO2019160904A1 (en) * 2018-02-15 2019-08-22 Macrogenics, Inc. Variant cd3-binding domains and their use in combination therapies for the treatment of disease
KR20210011002A (en) 2018-05-16 2021-01-29 얀센 바이오테크 인코포레이티드 Methods of treating cancer and methods of improving the efficacy of T-cell reinduction therapeutics
CN111116753A (en) * 2018-10-30 2020-05-08 上海泰因生物技术有限公司 A kind of preparation method of bispecific antibody
CN119569895A (en) 2018-11-01 2025-03-07 朱诺治疗学股份有限公司 G protein coupled receptor class C group 5 member D (GPRC 5D) specific chimeric antigen receptor
EP3891181A4 (en) * 2018-12-04 2022-08-17 Novartis AG BINDING MOLECULES AGAINST CD3 AND USES THEREOF
MA54513A (en) * 2018-12-21 2022-03-30 Hoffmann La Roche CD28 ANTIGEN BINDING MOLECULES TUMOR TARGETING AGONISTS
JOP20210194A1 (en) * 2019-01-18 2023-01-30 Janssen Biotech Inc The chimeric antigen receptor for GPRC5D and cells that express it
BR112021023048A2 (en) 2019-05-21 2022-04-19 Novartis Ag cd19 binding molecules and uses thereof
CN114729383A (en) 2019-07-02 2022-07-08 弗莱德哈钦森癌症研究中心 Recombinant AD35 vector and related gene therapy improvement
JP2022543551A (en) 2019-07-31 2022-10-13 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Antibody that binds to GPRC5D
BR112022001460A2 (en) * 2019-07-31 2022-03-22 Hoffmann La Roche Bispecific antigen-binding molecules, one or more isolated polynucleotides, host cell, method for producing a bispecific antigen-binding molecule and for treating a disease in an individual, pharmaceutical composition, use of the bispecific antigen-binding molecule and invention
JP7751577B2 (en) * 2019-12-06 2025-10-08 ジュノー セラピューティクス インコーポレイテッド Anti-idiotypic antibodies to the GPRC5D target binding domain and related compositions and methods
IL296514A (en) 2020-03-30 2022-11-01 Univ Mie Bispecific antibody
US12030937B2 (en) 2020-07-17 2024-07-09 Janssen Biotech, Inc. Anti-idiotypic antibodies against anti-GPRC5D antibodies
BR112023004830A2 (en) * 2020-09-16 2023-04-18 Janssen Biotech Inc METHODS FOR TREATMENT OF MULTIPLE MYELOMA
WO2022148370A1 (en) * 2021-01-05 2022-07-14 Lanova Medicines Development Co., Ltd. Anti-gprc5d monoclonal antibodies and uses thereof
IL304052A (en) * 2021-01-05 2023-08-01 Lanova Medicines Dev Co Ltd ANTI-GPRC5D MONOCLONAL ANTIBODIES AND THEIR USES
US12274747B2 (en) 2021-01-28 2025-04-15 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
AU2022221884A1 (en) 2021-02-16 2023-10-05 Janssen Pharmaceutica Nv Trispecific antibody targeting bcma, gprc5d, and cd3
AU2022223152A1 (en) * 2021-02-19 2023-08-31 Innovent Biologics (Suzhou) Co., Ltd. Anti-gprc5d×bcma×cd3 trispecific antibody and use thereof
JP7714675B2 (en) 2021-03-24 2025-07-29 ヤンセン バイオテツク，インコーポレーテツド Trispecific antibodies targeting CD79b, CD20, and CD3
TW202309522A (en) 2021-05-11 2023-03-01 美商健生生物科技公司 Methods and compositions for monitoring the treatment of relapsed and/or refractory multiple myeloma
WO2022247804A1 (en) * 2021-05-23 2022-12-01 上海祥耀生物科技有限责任公司 Anti-gprc5d antibody, preparation method therefor, and use thereof
JP2024540304A (en) 2021-11-03 2024-10-31 ヤンセン バイオテツク，インコーポレーテツド Reduction of corticosteroids during treatment with anti-CD38 antibodies
CN118159565A (en) * 2021-11-05 2024-06-07 正大天晴药业集团股份有限公司 Antibodies binding to GPRC5D and uses thereof
CA3241997A1 (en) 2021-12-21 2023-06-29 Taochao TAN Fully human antibody targeting gprc5d and chimeric antigen receptor (car) and use thereof
WO2023173272A1 (en) * 2022-03-15 2023-09-21 上海驯鹿生物技术有限公司 Gprc5d-targeting fully humanized chimeric antigen receptor (car) and use thereof
WO2023115347A1 (en) * 2021-12-21 2023-06-29 上海驯鹿生物技术有限公司 Fully human antibody targeting gprc5d
AU2022424142A1 (en) * 2021-12-31 2024-08-08 Kyinno Biotechnology Co., Ltd. Anti-gprc5d antibody and use thereof
CN118510805A (en) * 2021-12-31 2024-08-16 山东先声生物制药有限公司 GPRC5D antibody and application thereof
WO2023125729A1 (en) * 2021-12-31 2023-07-06 康源博创生物科技(北京)有限公司 Anti-cd3 humanized antibody and application thereof in preparation of bispecific antibody
US20250092135A1 (en) * 2022-01-10 2025-03-20 Nanjing Leads Biolabs Co., Ltd. Antibody and use thereof
WO2023143537A1 (en) * 2022-01-29 2023-08-03 恺兴生命科技(上海)有限公司 Gprc5d antibody and use thereof
WO2023174238A1 (en) * 2022-03-14 2023-09-21 江苏恒瑞医药股份有限公司 Antigen-binding molecule specifically binding to gprc5d and cd3 and medical use thereof
IL316002A (en) 2022-04-11 2024-11-01 Regeneron Pharma Universal tumor cell killing compositions and methods
AU2023275810A1 (en) * 2022-05-27 2024-12-12 Antengene Biologics Limited Novel anti-gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof
CN119317648A (en) * 2022-06-06 2025-01-14 山东先声生物制药有限公司 Multispecific antibodies targeting BCMA, GPRC5D and T cells and their applications
WO2024002308A1 (en) * 2022-06-30 2024-01-04 康诺亚生物医药科技（成都）有限公司 Development and use of novel multispecific tumor inhibitor
WO2024017326A1 (en) * 2022-07-21 2024-01-25 山东先声生物制药有限公司 Anti-gprc5d nanobody and use thereof
IL318416A (en) 2022-08-05 2025-03-01 Juno Therapeutics Inc Chimeric antigen receptors specific for gprc5d and bcma
CN116003598B (en) * 2022-08-30 2024-04-26 苏州缔码生物科技有限公司 Recombinant humanized monoclonal antibody targeting human GPRC5D and application thereof
JP2025529210A (en) 2022-09-01 2025-09-04 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド Compositions and methods for channeling apolipoprotein L1 to induce mammalian cell death - Patents.com
AU2022477506A1 (en) * 2022-09-09 2025-02-20 Beijing Mabworks Biotech Co., Ltd Multispecific antibody binding to bcma, gprc5d and cd3, and use thereof
TW202423969A (en) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Combination therapy of a gprc5d tcb and proteasome inhibitors
TW202423970A (en) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Combination therapy of a gprc5d tcb and cd38 antibodies
TW202430211A (en) 2022-10-10 2024-08-01 瑞士商赫孚孟拉羅股份公司 Combination therapy of a gprc5d tcb and imids
CN117924485A (en) * 2022-10-25 2024-04-26 上海祥耀生物科技有限责任公司 Multi-specific antibody for resisting GPRC5D
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
AU2023409727A1 (en) * 2022-12-22 2025-08-07 Janssen Pharmaceutica Nv Methods of preparing antibody-polynucleotide conjugates
TW202434644A (en) 2023-02-07 2024-09-01 大陸商上海齊魯製藥研究中心有限公司 Tri-specific antigen-binding molecules and uses thereof
WO2024173830A2 (en) 2023-02-17 2024-08-22 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies
TW202448927A (en) 2023-02-28 2024-12-16 美商健生生物科技公司 Compositions comprising a bispecific gprc5d/cd3 antibody
AU2023438363A1 (en) * 2023-03-22 2025-10-09 Biofront Therapeutics (Beijing) Co., Ltd. Nanobodies that bind to gprc5d and uses thereof
TW202448948A (en) * 2023-04-28 2024-12-16 大陸商正大天晴藥業集團股份有限公司 Bispecific antibodies targeting g protein-coupled receptors
WO2024235239A1 (en) * 2023-05-16 2024-11-21 上海齐鲁制药研究中心有限公司 Bispecific antigen binding molecule and use thereof
WO2024246856A1 (en) 2023-06-01 2024-12-05 Janssen Biotech, Inc. Methods for treating multiple myeloma
CN120129703A (en) * 2023-06-09 2025-06-10 德琪(杭州)生物有限公司 Novel antibodies targeting CD3 and another target and uses thereof
TW202500590A (en) * 2023-06-28 2025-01-01 大陸商浙江博銳生物製藥有限公司 Anti-gprc5d antibody and the pharmaceutical use thereof
WO2025019733A2 (en) * 2023-07-20 2025-01-23 Janssen Biotech, Inc. Methods for treating multiple myeloma
WO2025059362A1 (en) 2023-09-13 2025-03-20 Juno Therapeutics, Inc. Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
WO2025056013A1 (en) * 2023-09-13 2025-03-20 江苏恒瑞医药股份有限公司 Pharmaceutical composition comprising bispecific antibody specifically binding to gprc5d and cd3
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076472A1 (en) 2023-10-06 2025-04-10 Juno Therapeutics, Inc. Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
WO2025094085A1 (en) 2023-10-31 2025-05-08 Janssen Biotech, Inc. Combination regimens for treating multiple myeloma
WO2025134049A1 (en) 2023-12-21 2025-06-26 Janssen Biotech, Inc Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis
WO2025134050A1 (en) 2023-12-21 2025-06-26 Janssen Biotech, Inc Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of multiple myeloma
WO2025147545A1 (en) 2024-01-03 2025-07-10 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids and related methods and uses
CN117843788B (en) * 2024-01-09 2025-02-11 四川大学 An anti-GPRC5D antibody and its multispecific antibody and related applications
CN118108846B (en) * 2024-02-04 2024-11-26 四川大学华西医院 Preparation and application of allogeneic CAR-γδT cells targeting GPRC5D

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU4347701A (en) 2000-03-01 2001-09-12 Corixa Corp Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
AU2002367145A1 (en) * 2001-12-27 2003-07-15 Sumitomo Pharmaceuticals Co., Ltd. Remedies for anorexia or lifestyle-related diseases and method of screening the same
WO2005086568A2 (en) * 2004-01-26 2005-09-22 Morphosys Ag Anti-icam-1 human antibodies and uses thereof
CA2577082A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
WO2006106905A1 (en) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
DE102005028778A1 (en) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Multi-layer foil, useful for lining a flexible container, comprises a barrier layer, a stretch-poor plastic layer, an antistatic plastic layer and a layer containing a safe material for food
CA2625440C (en) 2005-10-11 2023-06-13 Micromet Ag Compositions comprising cross-species-specific antibodies and uses thereof
SG10201600950TA (en) 2005-11-28 2016-03-30 Genmab As Recombinant monovalent antibodies and methods for production thereof
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
KR101940944B1 (en) 2007-04-03 2019-01-22 암젠 리서치 (뮌헨) 게엠베하 Cross-species-specific cd3-epsilon binding domain
KR101589759B1 (en) 2007-04-03 2016-01-29 암젠 리서치 (뮌헨) 게엠베하 Species specific CD3-epsilon binding domain
MX2009010611A (en) 2007-04-03 2010-03-26 Micromet Ag Cross-species-specific bispecific binders.
WO2009085462A1 (en) 2007-12-19 2009-07-09 Centocor, Inc. Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
AU2009248049B2 (en) * 2008-05-16 2015-07-23 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
CA2738566C (en) 2008-10-01 2024-04-30 Micromet Ag Bispecific single chain antibodies with specificity for high molecular weight target antigens
WO2010037838A2 (en) 2008-10-01 2010-04-08 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
JP6126782B2 (en) 2008-10-01 2017-05-10 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー Cross-species specific PSMA × CD3 bispecific single chain antibody
MX2011004550A (en) 2008-10-31 2011-07-20 Centocor Ortho Biotech Inc Fibronectin type iii domain based scaffold compositions, methods and uses.
MX2011008566A (en) 2009-02-12 2011-11-29 Janssen Biotech Inc Fibronectin type iii domain based scaffold compositions, methods and uses.
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
KR101930964B1 (en) 2010-04-20 2018-12-19 젠맵 에이/에스 Heterodimeric antibody fc-containing proteins and methods for production thereof
KR101973930B1 (en) 2010-11-05 2019-04-29 자임워크스 인코포레이티드 Stable heterodimeric antibody design with mutations in the fc domain
CN107903325B (en) 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 Multispecific FAB fusion proteins and methods of use
KR102052774B1 (en) 2011-11-04 2019-12-04 자임워크스 인코포레이티드 Stable heterodimeric antibody design with mutations in the fc domain
FR2994803B1 (en) 2012-08-30 2016-02-26 Oreal MODULATION OF THE SHAPE OF KERATIN FIBERS
MY199162A (en) 2013-02-26 2023-10-18 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
BR112016022385A2 (en) 2014-03-28 2018-06-19 Xencor, Inc specific antibodies that bind to cd38 and cd3
WO2016036937A1 (en) 2014-09-05 2016-03-10 Janssen Pharmaceutica Nv Cd123 binding agents and uses thereof
ES2890669T3 (en) 2014-09-09 2022-01-21 Janssen Biotech Inc Combination therapies with anti-CD38 antibodies
WO2016090034A2 (en) 2014-12-03 2016-06-09 Novartis Ag Methods for b cell preconditioning in car therapy
CN113429484A (en) * 2014-12-05 2021-09-24 纪念斯隆-凯特琳癌症中心 Antibodies targeting G-protein coupled receptors and methods of use
CN107708734B (en) 2015-06-22 2022-01-11 詹森生物科技公司 Combination therapy of heme malignancies with anti-CD 38 antibodies and survivin inhibitors
WO2017031104A1 (en) 2015-08-17 2017-02-23 Janssen Pharmaceutica Nv Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof
PE20181310A1 (en) 2015-11-02 2018-08-10 Janssen Pharmaceutica Nv ANTI-IL1RAP ANTIBODIES, BI-SPECIFIC ANTIGEN BINDING MOLECULES THAT BIND IL1RAP AND CD3, AND USES OF THEM
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
TWI781108B (en) 2016-07-20 2022-10-21 比利時商健生藥品公司 Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof
WO2018147245A1 (en) 2017-02-07 2018-08-16 第一三共株式会社 Anti-gprc5d antibody and molecule containing same
WO2019094626A1 (en) 2017-11-08 2019-05-16 Fred Hutchinson Cancer Research Center Bispecific antibody compositions and related methods for improved pretargeted radioimunotherapies
BR112023004830A2 (en) 2020-09-16 2023-04-18 Janssen Biotech Inc METHODS FOR TREATMENT OF MULTIPLE MYELOMA
TW202309522A (en) 2021-05-11 2023-03-01 美商健生生物科技公司 Methods and compositions for monitoring the treatment of relapsed and/or refractory multiple myeloma

Also Published As

Publication number Publication date
CN109715667B (en) 2022-12-30
UY37340A (en) 2018-01-31
AR132097A2 (en) 2025-05-28
AR109499A1 (en) 2018-12-19
PE20190392A1 (en) 2019-03-13
KR20250073578A (en) 2025-05-27
CL2019000146A1 (en) 2019-04-26
JP2019527061A (en) 2019-09-26
KR102811945B1 (en) 2025-05-23
CO2019001114A2 (en) 2019-02-19
US20240343796A1 (en) 2024-10-17
LT3487882T (en) 2025-10-10
JP2023011774A (en) 2023-01-24
TWI781108B (en) 2022-10-21
EP3487882B1 (en) 2025-07-16
US20180037651A1 (en) 2018-02-08
IL264334B2 (en) 2024-05-01
MX2024001615A (en) 2024-02-28
MX2019000825A (en) 2019-09-04
EP3487882A2 (en) 2019-05-29
PE20240884A1 (en) 2024-04-24
FI3487882T3 (en) 2025-09-25
KR20230128409A (en) 2023-09-04
MX2023006449A (en) 2023-06-15
KR102572091B1 (en) 2023-08-31
WO2018017786A3 (en) 2018-03-01
BR112019001055A2 (en) 2019-10-01
KR20190028534A (en) 2019-03-18
DK3487882T3 (en) 2025-09-22
US20230227548A1 (en) 2023-07-20
CA3031472A1 (en) 2018-01-25
IN201917002488A (en) 2019-04-26
AU2017299673A1 (en) 2019-02-07
CL2024000444A1 (en) 2024-08-23
CL2024001015A1 (en) 2024-10-04
ECSP19012075A (en) 2019-02-28
JP7469432B2 (en) 2024-04-16
CN109715667A (en) 2019-05-03
US11884722B2 (en) 2024-01-30
CR20190025A (en) 2019-03-14
MA45712A (en) 2019-05-29
IL264334B1 (en) 2024-01-01
IL298277A (en) 2023-01-01
AU2024205021A1 (en) 2024-08-15
NI201900005A (en) 2019-05-10
US10562968B2 (en) 2020-02-18
EA201990346A1 (en) 2019-06-28
PH12019500152A1 (en) 2019-10-14
ZA201901066B (en) 2020-10-28
IL264334A (en) 2019-02-28
CN116333133A (en) 2023-06-27
AU2017299673B2 (en) 2024-08-01
US20230084967A1 (en) 2023-03-16
WO2018017786A2 (en) 2018-01-25
JP2024054176A (en) 2024-04-16
JP7292200B2 (en) 2023-06-16
TW201809005A (en) 2018-03-16
US11685777B2 (en) 2023-06-27
CL2024001016A1 (en) 2024-10-04

Similar Documents

Publication Publication Date Title
SG11201900468YA (en) Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof
SG11201908023YA (en) T cell receptors and immune therapy using the same against prame positive cancers
SG11201811290VA (en) Compositions and methods for the depletion of cd117+cells
SG11201907753TA (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201900677SA (en) Combination therapies of chimeric antigen receptors adn pd-1 inhibitors
SG11201810023QA (en) Anti-tim-3 antibodies and methods of use thereof
SG11201906468TA (en) Chimeric antigen receptors against axl or ror2 and methods of use thereof
SG11201807176XA (en) TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
SG11201810697QA (en) Chimeric antigen receptor and car-t cells that bind bcma
SG11201807489PA (en) Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201901307VA (en) Heterodimeric immunoglobulin constructs and preparation methods thereof
SG11202000330XA (en) Concept for generating an enhanced sound field description or a modified sound field description using a multi-point sound field description
SG11201805872SA (en) Chimeric antigen receptors targeting epidermal growth factor receptor variant iii
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201906192SA (en) Methods of treating cancer with anti-pd-1 antibodies
SG11201906319XA (en) Compositions and methods for the depletion of cd137+ cells
SG11201805268XA (en) T cell receptors specific for the ny-eso-1 tumor antigen-hla-a*02 complex
SG11201804127SA (en) Ctla4 binders
SG11201908784TA (en) Improved antigen binding receptor formats
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201903167QA (en) Compounds and methods for reducing atxn3 expression
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载